Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15078452 | 1.00 | CYP1A2 (0.41) | CYP1A2CYP3A4CYP2D6NFKB1PNMT | |
| SCHEMBL15078463 | 1.00 | CYP1A2 (0.41) | CYP1A2CYP3A4CYP2D6NFKB1PNMT | |
| SCHEMBL15078413 | 0.90 | CXCL8 (0.36) | ALDH1A1LMNAKMT2ACXCL8P2RX7 | |
| SCHEMBL10329426 | 0.90 | CXCL8 (0.36) | ALDH1A1LMNAKMT2ACXCL8P2RX7 | |
| SCHEMBL15078412 | 0.90 | CXCL8 (0.36) | ALDH1A1LMNAKMT2ACXCL8P2RX7 | |
| SCHEMBL15078410 | 0.90 | CXCL8 (0.36) | ALDH1A1LMNAKMT2ACXCL8P2RX7 | |
| SCHEMBL15078370 | 0.90 | CXCL8 (0.36) | ALDH1A1LMNAKMT2ACXCL8P2RX7 | |
| SCHEMBL15078460 | 0.86 | ALOX5 (0.32) | CYP1A2CYP3A4CYP2D6NFKB1ALDH1A1 | |
| SCHEMBL15078402 | 0.86 | ALOX5 (0.32) | CYP1A2CYP3A4CYP2D6NFKB1ALDH1A1 | |
| SCHEMBL15078449 | 0.86 | ALOX5 (0.32) | CYP1A2CYP3A4CYP2D6NFKB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3423433-B1 | SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES | BIO PHARM SOLUTIONS CO LTD (KR) | 2025-12-17 | — | — | EP | disclosed |
| US-10351519-B2 | Sulfamate derivative compounds, processes for preparing them and their uses | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2019-07-16 | — | — | US | disclosed |
| US-10351519-B2 | Sulfamate derivative compounds, processes for preparing them and their uses | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2019-07-16 | — | — | US | disclosed |
| EP-3423433-A1 | SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES | Bio-Pharm Solutions Co., Ltd. (KR) | 2019-01-09 | — | — | EP | disclosed |
| US-9504668-B2 | Phenyl alkyl carbamate compounds for use in preventing or treating epilepsy or epilepsy-related syndrome | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2016-11-29 | — | — | US | disclosed |
| US-9504668-B2 | Phenyl alkyl carbamate compounds for use in preventing or treating epilepsy or epilepsy-related syndrome | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2016-11-29 | — | — | US | disclosed |
| US-20160023999-A1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2016-01-28 | — | — | US | disclosed |
| US-20160023999-A1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2016-01-28 | — | — | US | disclosed |
| US-9029589-B2 | Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2015-05-12 | — | — | US | disclosed |
| US-9029589-B2 | Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2015-05-12 | — | — | US | disclosed |
| WO-2014142519-A1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2014-09-18 | — | — | WO | disclosed |
| WO-2013100566-A1 | Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2013-07-04 | — | — | WO | disclosed |
| US-20130165509-A1 | PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
| US-20130165509-A1 | PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351519-B2 | Sulfamate derivative compounds, processes for preparing them and their uses | STS, SULT2A1, SULT1A1 | CYP1A2 911/4885CYP3A4 1003/4885CYP2D6 871/4885 |
| US-20130165509-A1 | PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | MYLK, PDE3A, TNNC1 | CYP1A2 545/4885CYP3A4 58/4885CYP2D6 353/4885 |
| US-20160023999-A1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | SCN1A, GABARAPL1, NAA10 | CYP1A2 475/4885CYP3A4 860/4885CYP2D6 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.